Reaction

Limb Operation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,703 reports · 106 co-occurring drugs

As of the last recalculation, Limb Operation appears in 4,703 FAERS reports alongside 106 co-occurring drug terms. The strongest observed disproportionality signal is UPADACITINIB (PRR 19.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Upadacitinib	329	19.1	19.2
Cefazolin	35	17.1	17.2
Calcium, Magnesium, Potassium, And Sodium Oxybates	28	14.5	14.5
Rocuronium Bromide	37	14.0	14.0
Cefazolin Sodium	35	12.9	13.0
Risankizumab-Rzaa	194	10.9	10.9
Cyclobenzaprine Hydrochloride	13	6.4	6.4
Certolizumab Pegol	163	6.3	6.3
Abatacept	183	6.0	6.1
Ibrutinib	100	5.6	5.6
Ranolazine	13	5.5	5.5
Leflunomide	127	5.5	5.5
Alendronate Sodium	119	5.3	5.3
Tofacitinib	207	5.1	5.2
Hydroxychloroquine Sulfate	99	4.9	4.9
Belimumab	34	4.8	4.8
Tenofovir Disoproxil Fumarate	35	4.7	4.7
Hyoscyamine Sulfate	9	4.3	4.3
Infliximab-Dyyb	28	4.3	4.3
Bosentan	48	4.2	4.3
Meloxicam	54	4.2	4.2
Methocarbamol	21	4.1	4.1
Sodium Oxybate	60	4.1	4.1
Fluticasone Propionate And Salmeterol	38	4.1	4.1
Pancrelipase	35	4.0	4.0
Golimumab	77	4.0	4.0
Buspirone Hydrochloride	10	4.0	4.0
Methocarbamol Tablets	15	4.0	4.0
Bimekizumab	19	4.0	4.0
Patiromer	12	3.8	3.8
Oxymorphone Hydrochloride	10	3.8	3.8
Tofacitinib Citrate	11	3.7	3.7
Etanercept	465	3.7	3.7
Sitagliptin And Metformin Hydrochloride	18	3.7	3.7
Adalimumab	537	3.7	3.7
Naproxen	63	3.6	3.6
Liothyronine Sodium	7	3.6	3.6
Hydroxychloroquine	58	3.5	3.5
Umeclidinium	7	3.5	3.5
Biotin	24	3.4	3.4
Oxycodone And Acetaminophen Tablets	9	3.3	3.3
Methotrexate	292	3.2	3.2
Etonogestrel And Ethinyl Estradiol	16	3.2	3.2
Armodafinil	15	3.2	3.2
Lovastatin	17	2.9	2.9
Oral Semaglutide	48	2.9	2.9
Thyroid, Porcine	7	2.9	2.9
Infliximab	139	2.9	2.9
Tocilizumab	73	2.9	2.9
Losartan Potassium	49	2.8	2.8
Sarilumab	16	2.7	2.7
Timolol Maleate	6	2.7	2.7
Insulin Glulisine	6	2.6	2.6
Modafinil	19	2.6	2.6
Avapritinib	7	2.6	2.6
Sildenafil Powder,	20	2.5	2.5
Teriparatide	63	2.5	2.5
Linaclotide	15	2.5	2.5
Teriflunomide	25	2.5	2.5
Naltrexone	17	2.4	2.4
Macitentan	38	2.4	2.4
Vilazodone Hydrochloride	5	2.4	2.4
Agalsidase Beta	5	2.4	2.4
Cariprazine	5	2.4	2.4
Epoprostenol	7	2.4	2.4
Romosozumab-Aqqg	7	2.3	2.3
Tafamidis	6	2.3	2.3
Vibegron	4	2.2	2.2
Cenegermin-Bkbj	6	2.2	2.2
Rotigotine	7	2.1	2.1
Mepolizumab	24	2.1	2.1
Ambrisentan	60	2.1	2.1
Insulin Degludec	11	2.1	2.1
Conjugated Estrogens And Medroxyprogesterone Acetate	11	2.1	2.1
Bosutinib	4	2.0	2.0
Alirocumab	11	1.9	1.9
Insulin Glargine	105	1.9	1.9
Hydrocodone Bitartrate And Acetaminophen	22	1.7	1.7
Ivacaftor	3	1.7	1.7
Cinacalcet Hydrochloride	17	1.6	1.6
Guselkumab	13	1.6	1.6
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	15	1.6	1.6
Umeclidinium Bromide And Vilanterol Trifenatate	6	1.6	1.6
Vortioxetine	6	1.6	1.6
Liraglutide	17	1.5	1.5
Tolvaptan	5	1.5	1.5
Eptinezumab-Jjmr	3	1.5	1.5
Venetoclax	20	1.4	1.4
Dupilumab	153	1.4	1.4
Rimegepant Sulfate	4	1.4	1.4
Voxelotor	7	1.4	1.4
Abaloparatide	9	1.4	1.4
Esketamine Hydrochloride	5	1.2	1.2
Droxidopa	6	1.2	1.2
Erenumab-Aooe	15	1.2	1.2
Onabotulinumtoxina	21	1.2	1.2
Evolocumab	44	1.2	1.2
Fremanezumab-Vfrm	3	1.2	1.2
Relugolix	6	1.1	1.1
Lifitegrast	4	1.1	1.1
Valbenazine	6	1.1	1.1
Somatropin	16	1.0	1.0
Ixekizumab	8	1.0	1.0
Etonogestrel	10	0.9	0.9
Pimavanserin Tartrate	11	0.9	0.9
Apremilast	29	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.